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Abstract
Background: Publication bias compromises the validity of evidence-based medicine, yet a growing body of research shows
that this problem is widespread. Efficacy data from drug regulatory agencies, e.g., the US Food and Drug Administration
(FDA), can serve as a benchmark or control against which data in journal articles can be checked. Thus one may determine
whether publication bias is present and quantify the extent to which it inflates apparent drug efficacy.
Methods and Findings: FDA Drug Approval Packages for eight second-generation antipsychotics—aripiprazole,
iloperidone, olanzapine, paliperidone, quetiapine, risperidone, risperidone long-acting injection (risperidone LAI), and
ziprasidone—were used to identify a cohort of 24 FDA-registered premarketing trials. The results of these trials according to
the FDA were compared with the results conveyed in corresponding journal articles. The relationship between study
outcome and publication status was examined, and effect sizes derived from the two data sources were compared. Among
the 24 FDA-registered trials, four (17%) were unpublished. Of these, three failed to show that the study drug had a statistical
advantage over placebo, and one showed the study drug was statistically inferior to the active comparator. Among the 20
published trials, the five that were not positive, according to the FDA, showed some evidence of outcome reporting bias.
However, the association between trial outcome and publication status did not reach statistical significance. Further, the
apparent increase in the effect size point estimate due to publication bias was modest (8%) and not statistically significant.
On the other hand, the effect size for unpublished trials (0.23, 95% confidence interval 0.07 to 0.39) was less than half that
for the published trials (0.47, 95% confidence interval 0.40 to 0.54), a difference that was significant.
Conclusions: The magnitude of publication bias found for antipsychotics was less than that found previously for
antidepressants, possibly because antipsychotics demonstrate superiority to placebo more consistently. Without increased
access to regulatory agency data, publication bias will continue to blur distinctions between effective and ineffective drugs.
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Evidence-based medicine is valuable only to the extent that the
available evidence is complete and unbiased. Unfortunately,
whether research results are published, and how they are
published, often depends on their statistical significance [1,2],
which alters the apparent risk–benefit ratio of drugs. Within
medicine, a recent review found evidence for various forms of
publication bias within 40 different indications [3].
Despite ample evidence for the existence of publication bias,
there is little evidence of its quantitative impact on the apparent
efficacy of most drugs. Most methods for studying publication bias
provide indirect evidence for nonpublication or outcome reporting
bias. A frequently used method is to examine a cohort of published
studies for ‘‘small study effects’’ (smaller studies showing larger
treatment effects) in the form of funnel plot asymmetry [4].
Despite its wide use, this approach has limitations. First, although
a funnel plot may suggest that studies with smaller effect sizes have
not been published, it cannot prove that such studies in fact ever
existed. Second, the effect sizes plotted are based on results that
are published, and one cannot be sure whether and to what extent
such results have been affected by outcome reporting bias. The
true underlying results—the results according to the prespecified
outcomes—usually remain unknown.
By contrast, such data are often available from drug regulators,
such as the US Food and Drug Administration (FDA). Because the
FDA gathers data from premarketing trials both before inception
and after completion, it functions as both a registry and a results
database [5]. For any given cohort of trials, results according to
FDA reviews can be compared to corresponding results according
to the published literature. Any discrepancies between the two
sources provide direct evidence of publication bias.
FDA reviews have been used to document publication bias
across various medical indications in at least two studies [6,7]. An
advantage of looking broadly across medical indications is that it
documents the wide scope of publication bias, while focusing on a
single indication may lead some readers to assume that the
phenomenon is specific to that indication. On the other hand,
FDA data from a single indication may be more useful to meta-
analysts, since data measuring the same construct allow for the
calculation of an overall effect size. Such data should also be useful
to clinicians, who are interested in the true efficacy of a specific
drug class that they prescribe.
In a previous study of antidepressants, our group found that
publication bias nearly doubled the apparent proportion of
positive trials and increased the apparent effect size by one-third
[8]. This raises the question as to whether publication bias
similarly affects the apparent efficacy of other drug classes.
Schizophrenia has a lifetime prevalence of 0.55% [9], and its
core symptom, psychosis, is the third most disabling condition
worldwide [10]. The objective of this study is to use FDA data as
an independent benchmark or control to determine whether, and
to what extent, the apparent efficacy of second-generation
antipsychotics has been influenced by publication bias.
Methods
Ethics Statement
This study was approved by the Research and Development
Committee of the Portland Veterans Affairs Medical Center. It
was reported according to the guidelines of the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) group (Text S1).
Data Procurement
Procurement of data from FDA reviews. We identified the
phase 2/3 clinical trial programs leading to the FDA’s marketing
approval of eight second-generation antipsychotic drugs for the
treatment of schizophrenia. This retrospective cohort consisted of
24 FDA-registered short-term double-blind placebo-controlled
trials conducted between December 1993 and May 2005. The
FDA Drug Approval Packages were publicly available at, and
downloaded from, the FDA’s web site [5,11] for all drugs except
risperidone (Risperdal), for which we obtained the Drug Approval
Package via request to the FDA’s Freedom of Information Office.
(Because risperidone was approved in 1993, it was not subject to
the Electronic Freedom of Information Act of 1996 [12].) Within
the Drug Approval Packages, we examined data relevant to the
agency’s determination of drug efficacy in medical reviews,
statistical reviews, and administrative correspondence.
In order to make these documents more accessible to readers
and researchers, the FDA Drug Approval Package documents
were processed using Adobe Acrobat as follows: (1) reviews of the
same type but presented as multiple PDF files (e.g., Medical
Review Parts 1, 2, 3, and 4) were combined into single PDFs; (2)
page numbers were added as footers; (3) because the FDA had
presented the documents in an unsearchable format [5], they were
rendered searchable using optical character recognition; and (4)
text directly quoted in the present article was highlighted. These
documents have been placed in a digital repository of Oregon
Health & Science University. The reader may find them by
navigating to (1) http://www.ohsu.edu/library/, (2) ‘‘Digital
Resources Library,’’ then (3) ‘‘FDA Drug Approval Documents.’’
Procurement of data from journal articles (literature
search). The published literature was searched for journal
articles matching each FDA-reviewed trial, with a cutoff date of
May 5, 2010. The best match for each trial was identified using the
following parameters: drug name, name of active comparator
(when used), dosage groups, their sample sizes, trial duration, and
name of principal investigator.
The initial searches employed two databases, PubMed and
Cochrane Central Register of Controlled Trials. The search
strategy was for the title field to include the name of the drug and
either ‘‘schizophrenia’’ or ‘‘schizoaffective,’’ and for the word
‘‘placebo’’ to appear in any field (e.g., title, keywords, abstract). As
an example, when searching Cochrane Central Register of
Controlled Trials for relevant aripiprazole trials, the search syntax
was ‘‘(aripiprazole and schizo$).ti. and placebo.af.’’
From the search output, titles and abstracts were screened so as
to exclude journal articles focused on topics other than the overall
efficacy of the drug for schizophrenia or schizoaffective disorder.
Thus, articles focused on the following topics were excluded: other
indications (e.g., bipolar disorder, treatment-resistant schizophre-
nia), subsets with specific comorbid conditions, particular
symptom clusters (e.g., agitation, weight change), safety (as
opposed to efficacy), specific demographic samples, trials lacking
a parallel design (add-on, open-label, crossover), trials that were
not placebo-controlled, trials not involving acute treatment (long-
term trials, including maintenance trials), and trials involving other
routes of administration.
Trials were counted as published according to the method of
our earlier study [8]. The intent was to include journal articles that
provided data sufficient for meta-analysis yet were reasonably
discoverable by, and accessible to, the average clinician. Articles in
languages other than English were excluded. Meeting abstracts
were excluded—trials were required to be fully published [13]. An
FDA-registered trial was considered published if it could be
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primary publication was a stand-alone publication (i.e., an article
devoted to reporting the results of a single trial). If no stand-alone
publication could be found, aggregate publications, in which
multiple trials were covered in a single article, were sought.
However, aggregate publications were accepted only if all trials
included in the article presented primary data; aggregate
publications that were heterogeneous, i.e., those reporting a mix
of primary and secondary trial data, were excluded.
If the original searches using PubMed and the Cochrane
Central Register of Controlled Trials suggested that an FDA-
registered trial was unpublished, Ovid Medline was searched for
the three most recent review articles focused on the efficacy of the
drug in question. These review articles were then examined for
trial bibliographic information. The Ovid Medline search strategy
was similar to that given above for the Cochrane Central Register
of Controlled Trials, except that the search was restricted to review
articles in English and that ‘‘placebo’’ was omitted as a search
term. For example, when the original search yielded no journal
articles matching two FDA-registered trials of aripiprazole, the
following search strategy was used: (1) ‘‘(aripiprazole and
schizo$).ti. and review.pt.’’; (2) limit (1) to English language.
Finally, because pharmaceutical companies pledged in 2004 to
increase transparency by posting trial results publicly, the PhRMA
Clinical Study Results Database (decommissioned December
2011) and the drug sponsors’ own web sites were searched for
information as to whether these trials were published.
If all the above steps yielded no evidence of publication, it was
concluded that that the trial in question was not reasonably
accessible to the average clinician, and it was considered
unpublished.
Data Extraction and Entry
Double data extraction and entry was employed in this study.
The primary outcome was identified for each trial by two authors
(D. K. and L. S.) working independently, with the stipulation that
it be either the Brief Psychiatric Rating Scale (BPRS) [15] or the
Positive and Negative Syndrome Scale (PANSS) [16]. The two
raters’ sets of entries were compared, and any discrepancies were
resolved through consensus. The primary rating scale according to
the FDA matched that in the journal article for all trials but one.
Throughout the FDA reviews and journal articles, the primary
analyses involved modified intention-to-treat methods [17] for
handling dropouts: mixed-effects model repeated measures [18]
was used for some of the iloperidone trials (in both FDA reviews
and journal articles); last observation carried forward (LOCF) [19]
was used for all other trials. The numerical results according to the
primary outcome (p-values, means, standard deviations, standard
errors, and/or confidence intervals) were extracted and entered
independently by D. K. and L. S., for the FDA data followed by
the journal article data. Boolean formulas in Excel were used to
compare and flag any mismatches between the two sets of entries.
For each mismatch, the original data source (FDA review or
journal article) was re-examined by E. H. T. to determine which of
the two entries was correct.
In addition to the numerical or continuous data mentioned
above, categorical data were extracted. The FDA’s regulatory
decision on each trial was rated independently by D. K. and L. S.
at one of three levels: positive (supportive of efficacy), questionable
(neither clearly positive nor clearly negative), or negative (not
supportive of efficacy). Any discrepancies between the two sets of
ratings were discussed among the three authors while consulting
the FDA review materials, and consensus was reached. When the
judgment in the FDA’s review was unclear, the clinical trials
section of the original product labeling was downloaded from the
FDA web site and referred to for clarification. For each journal
publication, the presentation of the result on the primary outcome
was rated, again independently by D. K. and L. S., as positive,
negative, or questionable. Again, any differences between the two
sets of ratings were resolved by consensus.
For trials where the FDA ratings and journal ratings disagreed,
the authors shared and discussed their observations as to how they
disagreed. In contrast to our previously published study [8], the
differences found were, we felt, too varied and nuanced to be
meaningfully and reliably captured using a categorical rating
system and then subjected to statistical analysis. Instead, the
differences between the FDA and journal presentations of the trial
results are described in narrative format. This text was drafted by
E. H. T., critically revised by D. K. and L. S., and includes several
direct quotes from the data sources.
Data Analysis
Trial outcome versus publication status. As noted above,
the FDA’s regulatory decisions regarding the trials were classified
in this study as (1) positive (clearly supportive of efficacy), (2)
questionable (marginal or borderline support for efficacy), or (3)
negative (clearly not supportive of efficacy). Categories 2 and 3
were combined into a not-positive grouping. The strength of the
association between the FDA regulatory decision and publication
status (published versus unpublished) was calculated as Fisher’s
exact p (two-tailed) using the csi command with the exact option in
Stata 11 [20].
Meta-analysis. As described previously [8], two meta-
analyses were conducted: a conventional meta-analysis using
published data, and a control meta-analysis using FDA data. Data
from active comparators were excluded, so that each drug’s effect
size was derived solely from data collected by that drug’s sponsor.
The measure of effect size used was Hedges’s g [21], calculated
using the following equation [22]:
g~t|
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
n1
z
1
n2
s
ð1Þ
The values for g were adjusted using Hedges’s correction for small
sample size [23]. To calculate t, as previously described [8], precise
p-values were used together with the degrees of freedom as
arguments in Excel’s TINV function. If the p-value was instead
reported as a range (e.g., ‘‘p,0.05’’), collateral data to calculate
effect size were used according to the following hierarchy:
standard deviations, standard errors, and 95% confidence
interval around the mean difference. In the few cases where
none of these data were available in the journal article, data were
imputed from the FDA database. Conversely, when the FDA
database lacked the necessary data, data were imputed from the
corresponding journal article. The purpose of this imputation was
to err in the direction of the null hypothesis of no difference in
effect size between the FDA and the published literature. By
convention, positive and negative effect size values were used to
signify superiority and inferiority to placebo, respectively.
The typical trial compared multiple doses of study drug to
placebo (fixed-dose design). In such cases, a single trial-level effect
size and standard error was calculated using a fixed effects model
[24] to pool the values from that trial’s multiple treatment arms.
To avoid a spuriously low standard error, each trial’s shared
placebo n was counted once rather than redundantly for each dose
group. A limitation of this method is that it only partially addresses
error due to correlation between the comparisons [25].
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pooling method [26] in Stata [20,27] was used to calculate mean
weighted values for each drug and for the entire drug class.
Heterogeneity was assessed using the I
2 statistic [28]. As has been
recommended [29], 95% confidence intervals around I
2 were
calculated using the non-central chi-squared-based approach
within the heterogi module [30] for Stata.
As an error check, author E. H. T. returned to the dataset from
the original double data extraction and entry, repeated the
calculations, and electronically compared the resulting values with
those calculated earlier.
Meta-regression was conducted using the Metareg module for
Stata 11 [27] to contrast the FDA-based effect sizes of the
published trials with those of the unpublished trials. The method
used for estimating the between-study variance was residual
maximum likelihood, the default method in Stata 11. A similar
analysis was used to contrast the effect sizes derived from the FDA
data, from both published and unpublished trials, with the effect
sizes derived from the published literature.
Results
Number of Trials
According to the FDA reviews, the eight drugs examined were
approved based on the efficacy results from 24 short-term double-
blind placebo-controlled trials. Thus, three trials were required, on
average, to approve one second-generation antipsychotic. Table 1
shows the characteristics of these trials according to the FDA.
Table 2 shows bibliographic information on these trials. As seen,
20 of the trials (83%) were published and four (17%) were
unpublished. The 20 published trials were published in 19 journal
articles. The lack of one-to-one correspondence occurred because
(1) one article [31] reported the results of three iloperidone trials
(included because their results were not reported elsewhere in
stand-alone form—see Methods), and (2) one FDA-registered trial
of risperidone was published in two separate articles, one for the
Canadian sites and another for the US sites, as if they were
separate trials (details below).
Trial Outcome versus Publication Status
While most of the published trials (15/20=75%) were FDA-
positive, most of the unpublished trials (3/4=75%) were FDA-
negative or -questionable. The relationship between trial outcome
and publication status, shown in Figure 1, did not reach statistical
significance (Fisher’s exact test p=0.09). Handling the FDA-
questionable category in alternate ways yielded similar p-values
(see Table S1). In a post hoc analysis conducted after reclassifying
unpublished ziprasidone Trial 115 from positive to questionable
(in part because of its statistical inferiority to the active comparator
haloperidol—see narrative trial details below), this relationship did
reach statistical significance (p=0.012). When this trial was
excluded from the analysis, it remained significant (p=0.03).
Overall, according to the FDA reviews, two-thirds of the trials
(16/24=67%, binomial 95% confidence interval [CI95%] 45% to
84%) were positive, with the remaining one-third either question-
able or negative. By contrast, according to the journal articles,
there were 21 trials, all of them positive (CI95% 84% to 100%).
Meta-Analysis
The dose groups reported on in the journal articles matched
those in the FDA reviews. The statistical output from the two
meta-analyses, i.e., that of the FDA and that of the journal data, is
reproduced in Table S2 and Table S3, respectively. Figure 2 is a
forest plot of the effect size and confidence intervals based on the
data from the FDA reviews. For the published trials, the effect size
was 0.47 (CI95% 0.40 to 0.54; I
2 38%, CI95% 0% to 62%). For the
unpublished trials, the effect size was less than half that, 0.23
(CI95% 0.07 to 0.39; I
2 0%, CI95% 0% to 68%). By meta-
regression, the difference between the effect sizes for the published
versus unpublished trials was statistically significant (b=20.25,
CI95%20.47 to 20.03, t=22.36, p=0.027). Because the
unpublished trials were confined to two of the eight drugs, this
latter analysis was repeated while adding drug as an explanatory
variable. Here the effect of drug was not statistically significant
(b=0.02, CI95% 20.01 to 0.05, t=1.35, p=0.19), and the
difference between the published and unpublished trials remained
significant (b=20.28, CI95% 20.49 to 20.06, t=22.62,
p=0.016).
Within the published trials, there was essentially no difference
between the effect sizes derived from the FDA reviews (0.47 from
above) and those derived from the journal articles (0.48, CI95%
0.40 to 0.56; I
2 46%, CI95% 0% to 66%). By meta-regression, this
difference was not significant (b=0.002, CI95% 20.11 to 0.11,
t=0.03, p=0.98).
The FDA data from the published and unpublished trials were
combined into overall FDA-based effect sizes for each of eight
second-generation antipsychotics. These effect sizes, along with
their confidence intervals, are shown alongside their correspond-
ing journal-based effect sizes in Figure 3. For individual drugs, the
difference in effect size ranged from a 4% decrease (risperidone
LAI) to a 20% increase (ziprasidone). With all drugs combined, the
overall FDA-based effect size was 0.44 (CI95% 0.37 to 0.51; I
2
43%, CI95% 0% to 63%). Compared to this, the overall journal-
based effect size (0.48 from above) represented a slight (8%)
increase in effect size due to publication bias, which was
nonsignificant by meta-regression (b=0.03, CI95% 20.08 to
0.14, t=0.62, p=0.54). For each of the four effect sizes reported
above, the lower confidence limit for I
2 was zero, and the upper
confidence limit ranged from 62% to 68%, between proposed
landmarks for moderate and high levels of heterogeneity [32].
Unpublished Trials (n=4 Trials)
There were four trials for which we were unable to find any
evidence of publication. The literature search efforts are detailed
for each trial in Text S2. Following are details regarding the
conduct and results of these trials.
Unpublished aripiprazole trials (n=2). Aripiprazole Trial
94202 was one of two unpublished aripiprazole trials (Table 2). As
shown in Table 1, it involved over 200 patient-participants at 22
sites in the US. According to the FDA medical officer review
(pages 43 and 168 of 238), the data from one of the sites (site 003)
were excluded because its investigator (Richard Borison, M.D.,
Ph.D.) was ‘‘disqualified due to allegations of research misconduct
and conviction on criminal charges.’’ Neither the 10-mg dose nor
the 30-mg dose separated from placebo (p=0.89 and p=0.12,
respectively). The active comparator haloperidol separated from
placebo on one of the primary rating scales (BPRS core,
p=0.0495) but not the other (Clinical Global Impression Scale–
Improvement, p=0.08). Consistent with the former, the statistical
reviewer deemed the trial negative; consistent with the latter, the
medical reviewer deemed the trial ‘‘failed.’’ For our purposes, we
adopted the more conservative judgment of the study as failed, and
thus classified it as questionable (Figure 1).
Aripiprazole Trial 93202 involved over 100 patients at ten US
sites (Table 1). Like aripiprazole Trial 94202, aripiprazole did not
separate statistically from placebo (p=0.173), but unlike Trial
94202, the active comparator haloperidol clearly separated from
placebo (p=0.010). Thus, the FDA deemed Trial 93202 a
Publication Bias in Antipsychotic Trials
PLoS Medicine | www.plosmedicine.org 4 March 2012 | Volume 9 | Issue 3 | e1001189Table 1. Characteristics of premarketing trials of antipsychotics according to FDA.
Drug Being
Studied
Trial Number
or Identifier
Number of
Sites (Location)
Diagnoses
Included
Treatment
Arm
Duration
(wks)
Primary
Rating Scale
Baseline
Score
Scz Scz-Aff Drug Group
Dose
(mg) n Analyzed
Aripiprazole
(Abilify)
93202 10 (US) + 2 Aripiprazole 30 33 4 BPRSd 53
Haloperidol 20 33 50.3
Pbo 0 35 50
94202 22 (US) + 2 Aripiprazole 10 51 4 BPRS core 17
30 54 16.2
Haloperidol 10 54 16.6
Pbo 0 57 16.1
97201 36 (US) ++ Aripiprazole 15 99 4 PANSS 98.8
30 100 99.6
Haloperidol 10 99 99.9
Pbo 0 102 100.9
97202 40 (US) ++ Aripiprazole 20 98 4 PANSS 94
30 96 92.3
Risperidone 6 95 93.6
Pbo 0 103 95
138001 57 (US, Canada) + 2 Aripiprazole 10 103 6 PANSS 92.76
15 103 93.27
20 97 92.29
Pbo 0 107 92.4
Iloperidone
(Fanapt)
3000 45 (US) ++ Iloperidone 12 115 (82) 6 PANSS 94.6
Haloperidol 15 115 (70) 96.1
Pbo 0 117 (78) 95
3004 65 (No Am, So
Afr, Eur, Australia)
++ Iloperidone 10–16 149 (121) 6 BPRSd 54.1
Risperidone 4–8 146 (110) 54.7
Pbo 0 152 (116) 54.2
3005 67 (No Am, So
Afr, Isr, Eur)
++ Iloperidone 12–16 230 (178) 6 BPRSd 54.4
20–24 141 (111) 54.9
Risperidone 6–8 148 (119) 55
Pbo 0 152 (113) 55.4
3101 44 (US, India) + 2 Iloperidone 24 283 4 PANSS 92.88
Ziprasidone 160 144 90.95
Pbo 0 140 90.48
Olanzapine
(Zyprexa)
HGAD 23 (US, Canada) + 2 Olanzapine 10 62 6 BPRS 42.84
15 65 42.62
Haloperidol 15 68 41.79
Pbo 0 62 39.69
HGAP 12 (US) + 2 Olanzapine 10 49 6 BPRS 37.43
Pbo 0 49 36.78
Paliperidone
(Invega)
303 53 (Eastern and
Western Eur)
+ 2 Paliperidone 6 123 6 PANSS 94.3
9 122 93.2
12 129 94.6
Pbo 0 126 94.1
304 45 (US) + 2 Paliperidone 6 110 6 PANSS 92.3
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Drug Being
Studied
Trial Number
or Identifier
Number of
Sites (Location)
Diagnoses
Included
Treatment
Arm
Duration
(wks)
Primary
Rating Scale
Baseline
Score
Scz Scz-Aff Drug Group
Dose
(mg) n Analyzed
12 111 94.1
Olanzapine 10 105 —
Pbo 0 105 93.6
305 74 (No Am, Eastern
Eur, Asia, Isr, Mex, So
Afr)
+ 2 Paliperidone 3 123 6 PANSS 91.6
9 123 93.9
15 113 92.4
Olanzapine 10 — —
Pbo 0 120 93.9
Quetiapine
(Seroquel)
0001/0008 37 (US, Eur) + 2 Quetiapine #250 92 6 BPRS 38.89
#750 94 41.04
Pbo 0 94 38.35
0006 11 (US) + 2 Quetiapine 75–750 53 6 BPRS 55.79
Pbo 0 53 54.09
0013 26 (US, Canada) + 2 Quetiapine 150 48 6 BPRS 47.15
300 51 45.29
600 51 43.45
750 53 45.72
Haloperidol 12 50 44
Pbo 0 51 45.31
Risperidone
(Risperdal)
201 9 (US) + 2 Risperidone 1–10 51 6 BPRS 56.2
Haloperidol 20 52 53.1
Pbo 0 53 52.8
204 28 (US, Canada) + 2 Risperidone 6 85 8 PANSS 94.9
10 85 91.8
16 85 93.9
Haloperidol 20 85 93.6
Pbo 0 86 92.6
Risperidone LAI
(Consta)
RIS-USA-121 47 (US) + 2 Risperidone LAI 25 93 12 PANSS 81.7
50 98 82.3
Pbo 0 92 82
Ziprasidone
(Geodon)
104 17 (US) ++ Ziprasidone 40 55 4 BPRS 34.5
80 47 36.2
Pbo 0 47 33.4
106 12 (US) ++ Ziprasidone 40 43 4 BPRS 36.5
120 41 36.6
Pbo 0 47 37
114 34 (US, Canada) ++ Ziprasidone 80 104 6 BPRSd 56.5
160 103 55
Pbo 0 91 55.1
115 54 (US) ++ Ziprasidone 40 86 6 BPRSd 53.8
120 76 51.8
200 82 51.8
Haloperidol 15 82 53.9
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published.
Unpublished ziprasidone trials (n=2). Ziprasidone Trial
115 was one of two unpublished ziprasidone trials (see Text S2 for
results of literature search). As seen in Table 1, ziprasidone Trial
115 involved 53 US sites and over 400 patients and five treatment
arms: three doses of ziprasidone (20 mg bid, 60 mg bid, and
100 mg bid), placebo, and haloperidol 10 mg as an active
comparator. All active treatment arms demonstrated statistical
superiority to the placebo arm, and there was evidence of a
positive dose–response relationship. Because the FDA judges
efficacy based on whether the study drug demonstrates superiority
to placebo, the trial was ultimately considered positive.
Earlier, however, efficacy results from this trial, together with a
safety concern, proved to be a temporary obstacle to marketing
approval. When ziprasidone was first being reviewed, the FDA
was concerned about the drug’s tendency to prolong the QT
interval and how that might affect the overall risk–benefit ratio
and, consequently, its approvability. The cardiology consultant is
quoted within the medical review (page 2 of 223):
Table 1. Cont.
Drug Being
Studied
Trial Number
or Identifier
Number of
Sites (Location)
Diagnoses
Included
Treatment
Arm
Duration
(wks)
Primary
Rating Scale
Baseline
Score
Scz Scz-Aff Drug Group
Dose
(mg) n Analyzed
Pbo 0 80 54.3
Drug brand name shown in parentheses. A dash indicates that the baseline score is not available in the FDA review. For aripiprazole Trial 94202, the number of sites is
based on FDA analysis, which excluded site #003 (see text). For the first three iloperidone trials, parentheses enclose the sample size of the subset of patients with
schizophrenia analyzed by the FDA. Dose groups shown only if within FDA-approved dose range. For paliperidone Trials 304 and 305, the FDA review did not list results
for the olanzapine group: the corresponding n was taken from the corresponding journal article.
BPRSd, BPRS score derived from PANSS score; Eur, Europe; Isr, Israel; Mex, Mexico; No Am, North America; Pbo, placebo; So Afr, South Africa; Scz, schizophrenia; Scz-Aff,
schizoaffective disorder.
doi:10.1371/journal.pmed.1001189.t001
Table 2. Bibliographic information on FDA-registered antipsychotic trials.
Sponsor Drug Name
Trial Number
or Identifier First Author Year Journal Name PubMed ID Reference
AstraZeneca Quetiapine 0006 Borison 1996 J Clin Psychopharmacol 8690831 [35]
0001/0008 Small 1997 Arch Gen Psychiatry 9193196 [57]
0013 Arvanitis 1997 Biol Psychiatry 9270900 [58]
BMS Aripiprazole 93202 Unpublished
94202 Unpublished
97201 Kane 2002 J Clin Psychiatry 12363115 [59]
97202 Potkin 2003 Arch Gen Psychiatry 12860772 [60]
138001 McEvoy 2007 J Psychiatr Res 17631314 [61]
Janssen Paliperidone 303 Kane 2007 Schizophr Res 17092691 [62]
304 Marder 2007 Biol Psychiatry 17601495 [63]
305 Davidson 2007 Schizophr Res 17466492 [64]
Risperidone 201 Borison 1992 Psychopharmacol Bull 13811002 [37]
204 (US sites) Marder 1994 Am J Psychiatry 7514366 [41]
204 (Canadian sites) Chouinard 1993 J Clin Psychopharmacol 7683702 [40]
Risperidone LAI RIS-USA-121 Kane 2003 Am J Psychiatry 12777271 [65]
Lilly Olanzapine HGAD Beasley 1996 Neuropsychopharmacology 8822534 [66]
HGAP Beasley 1996 Psychopharmacology (Berl) 8935812 [67]
Novartis/Vanda Iloperidone 3000 Potkin 2008 J Clin Psychopharmacol 18334911 [31]
3004
3005
3101 Cutler 2008 J Clin Psychopharmacol 18334909 [34]
Pfizer Ziprasidone 104 Unpublished
106 Keck 1998 Psychopharmacology (Berl) 9860108 [36]
114 Daniel 1999 Neuropsychopharmacology 10192829 [68]
115 Unpublished
doi:10.1371/journal.pmed.1001189.t002
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suggests superior benefit over currently available drugs,
ziprasidone should be considered for second line therapy
with adequate warnings of risk associated with drugs that
prolong the QT interval.’’
Ziprasidone Trial 115 was the only premarketing trial in which
ziprasidone was compared to a marketed antipsychotic as well as
to placebo. In this trial, ziprasidone failed to show the above-
mentioned ‘‘superior benefit over currently available drugs.’’ In
fact, it showed the opposite, that ziprasidone was statistically
inferior to the active comparator haloperidol. According to the
statistical review (page 7 of 61):
The haloperidol (active control) seemed to have a larger
decrease in changes from baseline for most of the primary
efficacy endpoints.
This statement was followed in the statistical review by Table 1R,
which documented the statistical superiority of haloperidol over
ziprasidone in this trial. In the column comparing the combination
of all three ziprasidone dose groups to haloperidol, the p-values
achieved on the scales BPRS total, BPRS core, Clinical Global
Impression Scale–Severity, PANSS total, and PANSS negative
symptoms were 0.037, 0.002, 0.002, 0.017 and 0.335, respectively.
Thus, ziprasidone was statistically inferior to haloperidol on four of
the five scales. The statistical reviewer also noted (page 7 of 61):
The secondary objective comparing haloperidol with
ziprasidone was changed to that of comparing haloperidol
with placebo after the completion of the trial
[emphasis in original].
Thus, with respect to the original secondary objective, Trial 115
was negative. (The fact that this trial could be considered positive
is because secondary outcomes are trumped by primary outcomes,
which involved comparisons of ziprasidone to placebo.) Weighing
the overall risk–benefit ratio of ziprasidone during the earlier
review cycle, the medical review (page 3 of 223) quoted the
Division Director:
‘‘[Z]iprasidone’s comparative performance (Study 115)
s u p p o r t sac o n c l u s i o nt h a ti ti sl e s se f f i c a c i o u st h a n
haloperidol, a long marketed antipsychotic drug.’’ Dr. Leber
[the Division Director] recommended a nonapprovable
action….The nonapprovable letter of June 17
th, 1998
asserted that a sufficient advantage over currently marketed
antipsychotics had not been demonstrated that could
outweigh the risk of potentially fatal arrhythmias because
of the demonstrated QTc prolongation.
Later, a July 2000 Advisory Committee recommended that the
FDA approve ziprasidone in spite of the QT issues. Following this,
theinferiorperformanceofziprasidonerelativetohaloperidolceased
to be a concern, so Trial 115 could be considered, from a regulatory
standpoint,supportive of efficacy.Based onthisfinaljudgment ofthe
FDA,Trial115 isclassifiedas positive inFigure 1and inourprimary
statistical analysis and as questionable in a post hoc analysis.
The results of another ziprasidone trial, Trial 104, were not
published. Table 1 shows that, in Trial 104, two doses of
Figure 1. Trial outcome according to the FDA versus publication status of 24 premarketing trials of eight second-generation
antipsychotics. Published trials are shown as white boxes, unpublished trials are shown as black boxes, and the trial numbers are shown within the
boxes. Unpublished trials were, with one exception, not positive (either negative or questionable). Please see the text for narrative descriptions of
several of these trials. Please note that the number of white boxes does not equal the number of journal articles (see text and Table 2): iloperidone
trials 3000, 3004, and 3005 were published in a single journal article, and risperidone trial 204 was published as two separate journal articles, as
though the US and Canadian sites constituted two distinct positive trials.
doi:10.1371/journal.pmed.1001189.g001
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PLoS Medicine | www.plosmedicine.org 8 March 2012 | Volume 9 | Issue 3 | e1001189Figure 2. Forest plot of effect size (Hedges’s g) values for FDA-registered premarketing trials of second-generation antipsychotics.
The black horizontal bars highlight the four unpublished trials, three of which demonstrated no statistically significant advantage for the drug over
placebo. The fourth unpublished trial showed that the drug was superior to placebo but statistically inferior to the active comparator haloperidol.
Below the first dotted horizontal line, subtotal effect size and confidence interval values are shown for the subset of published trials and for the
subset of unpublished trials. The difference in effect size between the published and unpublished trials was statistically significant (see text). Below
the second dotted horizontal line, the FDA-based effect size is shown for all trials combined (0.44). The effect sizes shown for iloperidone trials 3000,
3004, and 3005 are based on the full sample of patients recruited, i.e., those with either schizophrenia or schizoaffective disorder, as opposed to the
subset of patients with schizophrenia only (see text for details).
doi:10.1371/journal.pmed.1001189.g002
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PLoS Medicine | www.plosmedicine.org 9 March 2012 | Volume 9 | Issue 3 | e1001189Figure 3. Forest plot of mean weighted effect size (Hedges’s g) values by drug and data source. The figure is sorted according to the
effect size point estimates derived from the FDA data; these are shown with gray-filled squares. The point estimates derived from the corresponding
journal articles are shown with open circles. Horizontal lines indicate 95% confidence intervals around the effect size point estimates. The right-hand
column shows the percent differences between the FDA-based and the journal-based effect size point estimates. (These percent differences are
based on estimates accurate to three decimal places, while the estimates shown are rounded to two decimal places.) The differences ranged from
24% to +20%, depending on the drug. For the entire drug class (labeled ‘‘overall antipsychotics’’), publication bias increased apparent effect size by
8%. To provide context, previously published data on antidepressants [8] are shown at the bottom in gray. Note that the 8% increase with
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dose group of 10 mg/d, but it is not shown in the table or included
in our analyses because that dose was not approved by the FDA.
This trial involved nearly 200 patients (including the patients
assigned to the low-dose group) at 17 US sites. According to the
FDA statistical review (pages 16 and 12 of 61):
None of the three primary efficacy endpoints reached
statistical significance at two-sided 0.05 level either based on
the ITT LOCF or the Completer analyses in Study
104….There was no dose-response trend either including
or excluding placebo with respect to any of the primary
endpoints.
Outcome Reporting Bias (n=5 Trials)
Among the eight trials classified as having FDA-negative or -
questionable outcomes (Figure 1), five were published. The FDA
reviews of these five trials presented data that raised concerns
about drug efficacy. Below we note whether and how these
concerns were conveyed in the corresponding journal articles.
Iloperidone trials (n=3). One efficacy issue that was
apparent from the FDA review of iloperidone, but not from the
corresponding journal articles, was that the drug frequently proved
to be statistically inferior to active comparators (Table 3 and
detailed below).
Another issue apparent from the FDA review was that
iloperidone’s efficacy relative to placebo varied according to the
patient diagnostic population studied. Consequently, as has been
reported previously [33], iloperidone’s path to FDA approval was
somewhat convoluted. To elaborate, of the four iloperidone
premarketing trials, the first three called for the recruitment of
patients diagnosed with either schizophrenia or schizoaffective
disorder: Trials 3000, 3004, and 3005. The protocols for these
three trials were submitted to and approved by the FDA, and these
trials were conducted between 1998 and 2001. The results of these
three trials were presented together in a single 2008 journal article
[31].
In contrast to the way these trials were reported in the journal
article (details below), the FDA review initially judged only one of
the three trials to be positive (Trial 3004; Table 3). Because the
FDA requires two positive studies in order to approve a drug for
marketing, the agency informed the drug’s sponsor in 2001 that
another positive trial would be required for approval. The agency
added that such a trial should be restricted to patients with
schizophrenia, i.e., excluding patients with schizoaffective disor-
der.
A fourth premarketing trial, restricted to patients with
schizophrenia, was undertaken in 2005. The results from this
trial were positive, and they were submitted to the FDA in a New
Drug Application (NDA) in November 2007. On July 25, 2008,
the agency issued a not-approvable letter, stating that the sponsor
had failed to demonstrate efficacy (through two or more positive
trials) in patients with schizophrenia.
After the sponsor appealed the decision, the FDA conducted a
post hoc reanalysis of the first three trials, examining efficacy
within the subset of patients diagnosed with schizophrenia, i.e.,
excluding data from the patients in those trials diagnosed with
schizoaffective disorder. This reanalysis yielded a positive result for
one of the initial three trials, Trial 3005 (Table 3). This positive
result from Trial 3005, together with the positive result from Trial
3101, yielded a total of two positive trials in patients with
schizophrenia. The FDA’s criterion for approval, i.e., two or more
positive trials in a defined patient population, was now achieved,
thus allowing the agency to approve iloperidone in May 2009.
Iloperidone Trial 3000. In iloperidone Trial 3000, according
to the FDA, the dose group prespecified in the protocol as primary
antipsychotics is much less than the 32% increase with antidepressants [8]. Also, the journal data show only a 16% advantage in effect size for
antipsychotics over antidepressants (from 0.41 to 0.48), while FDA data reveal a much larger advantage (42%, from 0.31 to 0.44).
doi:10.1371/journal.pmed.1001189.g003
Table 3. Iloperidone results (p-values) by trial, dose group, and diagnosis.
Trial Number/
Measure
Primary Dose
Group(s) (mg/d)
Schizophrenia+Schizoaffective
Disorder (All Patients)
Schizophrenia Only (Post Hoc FDA
Subset)
p-Value
Highlighted in
Journal Article
Superiority
versus Placebo
Inferiority versus
Active Comparator
Superiority
versus Placebo
Inferiority versus
Active Comparator
3000 8+12 0.065 0.027 0.148 0.063 0.047 (12 mg only)
3004 10–16 0.001 0.034 0.306 0.021 0.001
3005 12–16 0.059 ,0.001 0.033 0.005 0.09
20–24 0.071 0.034 0.005 0.093 0.01
3101 24 Schizoaffective patients not recruited 0.007 FDA reported as
statistically inferior
without p-values
,0.01
Total number of positive trials 1 0 2 0 4
Total number negative
or questionable trials
23 22 0
Meets FDA approval criterion
of two or more positive trials
N o —Y e s ——
Statistically significant p-values (,0.05) are given in bold. Column at far right shows p-values from journal articles; all others are from the FDA review of iloperidone. See
text for details.
doi:10.1371/journal.pmed.1001189.t003
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iloperidone per day. For this combined dose group, using the full
schizophrenia-plus-schizoaffective sample of patients, the drug–
placebo differencewas nonsignificant (p=0.065).The corresponding
journal article [31] reported this nonsignificant p-value in the text of
the results section but preceded this with the report of a significant
finding (p=0.047) obtained with the 12-mg dose alone, a secondary
outcome. This significant result was also reported in the abstract,
while the nonsignificant result on the primary dose group was not.
The FDA’s findings that iloperidone was statistically inferior to
haloperidol for this all-patients sample (p=0.027; Table 3) was not
reported in the corresponding journal article. Additionally, the
FDA’s finding of a lack of statistical superiority to placebo (p=0.148)
with the schizophrenia-only subset was not reported in the journal
article [31]. However, the sponsor did not learn of the FDA’s intent
to focus on the schizophrenia-only subset until the not-approvable
letter was issued (July 2008), some months after the journal article
was published (April 2008).
Iloperidone Trial 3004. Among the three iloperidone trials
that recruited patients diagnosed with either schizophrenia or
schizoaffective disorder, Trial 3004 was the only one for which the
FDA found significant results for the all-patients sample (Table 3).
We have classified it as questionable for two reasons. First,
although the FDA initially judged this trial to be positive based on
the all-patients sample, it later conducted a post hoc analysis on
the subset of patients with schizophrenia, which yielded a
nonsignificant result (p=0.306). Commenting on this finding, the
FDA medical reviewer stated (page 110 of 247):
The results of Study 3004 do not provide evidence of
efficacy of iloperidone…in the treatment of schizophrenia
versus placebo over 42 days of treatment.
Second, the FDA found that iloperidone was significantly
inferior to the active comparator risperidone (Table 3), both for
the subset of patients with schizophrenia (p=0.021) and for the all-
patients group (p=0.034). According to the summary review by
Division Director Thomas Laughren (page 6 of 21):
Thus, either approach to defining the sample for this study
yields a result that favors a standard control agent over
iloperidone.
This statistical inferiority to risperidone was not reported in
published version of this trial [31].
Iloperidone Trial 3005. Trial 3005 also yielded a mix of
positiveandnot-positiveefficacyresults.Aswiththeotheriloperidone
trials, the FDA review revealed evidence of iloperidone’s statistical
inferioritytotheactivecomparator(Table3).Additionally,fortheall-
patients (schizophrenia-plus-schizoaffective) sample, the FDA found
that the 0.05 threshold for statistical significance was not achieved for
either dose group, while the journal publication [31] reported a
significant result (p=0.01) for one of the two dose groups.
In the FDA’s post hoc analysis of the subset of patients with
schizophrenia, the results were significant for both dose groups
(p=0.033 and p=0.005, respectively). Thus, as a result of the
FDA’s reanalysis using this patient subset, the results of Trial 3005
changed from nonsignificant to significant, the opposite of what
occurred with the reanalysis of Trial 3004. As was the case for the
other two trials covered in this journal article [31], the results
based on this patient subset were not reported. As can be seen in
Table 3, these results were favorable for Trial 3005 (though
unfavorable for Trials 3000 and 3004). As stated above, the fact
that Trial 3005 was positive in the schizophrenia-only subset
allowed the FDA to approve iloperidone: by focusing on patients
with schizophrenia and combining this result with that of Trial
3101, the FDA’s requirement of two positive trials was achieved.
Iloperidone Trial 3101. Trial 3101 was the only iloperidone
premarketing trial to include only patients with schizophrenia and
exclude those with schizoaffective disorder. As shown in Table 3,
iloperidone demonstrated superiority to placebo (p=0.007). How-
ever,theFDAalsoreportedthatiloperidonewassignificantlyinferior
to the active comparator (ziprasidone in this trial) in most of the
comparisons. (These p-values were not reported in the FDA review,
so they do not appear in Table 3.) As with the above-mentioned
trials, iloperidone’s statistical inferiority to the active comparator was
not reported in the corresponding journal article [34].
Quetiapine Trial 0006. We also classified quetiapine Trial
0006 as questionable, rather than clearly positive or negative.
According to the FDA medical officer’s conclusion (page 82 of
245):
On balance, this study provides marginal support for
antipsychotic efficacy of quetiapine, when titrated to a wide
dose range. Strictly speaking, however, the data fall short of
meeting the customary level of statistical proof, particularly
for the observed cases [completers] analyses.
Regarding this same trial, the statistical reviewer stated (page 2
of 40):
The borderline statistical result of the LOCF [the protocol-
prespecified primary method for handling dropouts;
p=0.07] is likely due to the less than anticipated treatment
difference at 6 weeks (28.1 versus 22.1). Note that there
was no difference at all for the completers. [For example,
using the BPRS rating scale, p=0.95.] Thus, Figure 5
indicates that the entire treatment difference in the LOCF
analysis is due to dropouts in the first 4 weeks of the trial.
The corresponding journal article [35] communicated the
results of this trial with more favorable language. The abstract
opened its presentation of the results with the following:
Significant differences (p equal to or less than 0.05) between
treatment groups, which favored ICI 204,636 [quetiapine],
were identified throughout the trial.
The results section opened its efficacy section with the following:
On days 14, 28, and 35, when statistically significant
differences between treatment groups were detected, mean
changes in BPRS total scores were….
In the sentence that followed, the above-mentioned p-value of
0.07 was reported and described as ‘‘marginally significant and
favored ICH 204,636 [quetiapine].’’ Following that, four p-values
above the 0.05 significance threshold were listed and described as
‘‘marginally significant.’’ The results of the completers analyses,
described by the FDA as showing ‘‘no difference at all’’ (see
above), were not reported in the journal article.
Ziprasidone Trial 106. We have classified ziprasidone Trial
106 as neither clearly positive nor negative, but rather
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review stated:
Because this study showed statistical significance in only two
of the three primary efficacy variables in week 4 only, it
merely provides fair evidence for the antipsychotic proper-
ties of ziprasidone at a dose of 60 mg bid.
The FDA’s point—that the efficacy of the 120-mg dose was in
question because it failed to demonstrate superiority to placebo on
all primary outcomes—was not apparent in the journal article
[36], which stated:
In the intent-to-treat analysis of mean changes from baseline
at 4 weeks, ziprasidone 120 mg/day was significantly more
effective than placebo in improving mean BPRS total and
CGI-S [Clinical Global Impression Scale–Severity] scores
(P,0.05).
Second, a 40-mg/d (20 mg twice daily) dose group was included
in this trial, and though it demonstrated efficacy in other trials and
thus became an FDA-approved dose, it did not demonstrate
statistical superiority to placebo in this trial on any of the three
primary variables (e.g., p=0.657 on the BPRS).
In the published version of this trial [36] the nonsignificance of
the results at this dose were acknowledged, but without p-values
and, compared to the 120-mg findings, less prominently in terms of
placement. In the results section, while the 120-mg/d results were
mentioned in the first line of the efficacy subsection, the 40-mg
results were mentioned in the ninth line. In the discussion section,
while the significant 120-mg results were mentioned in the first line,
the nonsignificant 40-mg results were mentioned in the middle of
the third paragraph. The abstract reported several significant results
for the 120-mg dose but no results for the 40-mg dose.
Selective Reporting of Sites within Trials (n=2 Trials)
Risperidone Trial 201. According to the FDA review,
risperidone Trial 201 involved nine US sites. The total baseline
sample consisted of 160 patients, of whom 156 were included in
the LOCF analysis, this trial’s primary method of handling
dropouts. The corresponding journal article [37] reported a total
sample size of only 36. The number of sites was not reported. No
additional publications arising from this trial could be identified in
our literature search or within a meta-analysis on risperidone [38]
published four years later.
Because the FDA review did not break down Trial 201’s results
by site, it is unknown whether the published results were any more
favorable to risperidone than those that were not published.
Nevertheless, the overall results were positive according to both
the FDA and the journal article. According to the FDA:
Study 201 provides unequivocal support for the effectiveness
of risperidone as an antipsychotic agent.
Thus, there was evidence that the data from this trial were
selectively reported in terms of the patients reported on, but this
situation does not appear to meet criteria for publication bias in
that it did not affect the strength and direction of the results [39],
at least with respect to efficacy.
Risperidone Trial 204. According to the FDA review,
risperidone Trial 204 was a single multicenter trial conducted at
26 sites, 20 in the US and six in Canada. Being a multicenter trial,
the data from all sites were pooled in the FDA analysis. Rather
than publish the results of this trial in a single journal article, the
sponsor published reported the data results from the six Canadian
sites in a 1993 journal article [40] as one positive trial and the data
from the 20 US sites in a 1994 article [41] as a separate positive
trial. The first article did not mention the US sites. The second
article stated:
In the present article we report the results of a multicenter
study of schizophrenic patients recruited at 20 centers in the
United States. The study is part of a U.S.-Canadian
collaborative investigation of risperidone in schizophrenia.
The results of the Canadian arm of the investigation have
been published [citation referencing [42]].
Three years later, the drug’s sponsor reported the US and
Canadian sites’ results in a single article [42], but the article’s first
sentence stated:
Two pivotal controlled trials of risperidone have been
conducted in North America, the Canadian study of
Chouinard et al [citation referencing [40]] and the United
States study of Marder and Meibach [citation referencing
[41]]. In this report, we present the results of an analysis of
the combined data from the two trials….
Therefore, while the FDA was aware that this was a single trial
and analyzed it as such, readers, editors, and reviewers of journal
articles would have thought they were reading two different trials.
This ‘‘split’’ is shown with a horizontal dotted line in Figure 1, and
it contributed to the lack of one-to-one correspondence between
the FDA studies and journal articles shown in Table 1.
Discussion
Recapitulation of Findings
These data provide mixed evidence for publication bias for
antipsychotic drug trials. One-sixth (17%) of the trials were
unpublished. Among the four unpublished trials, three failed to
showthatthe drugwassuperiortoplacebo,and oneshowedthatthe
drug was statistically inferior to the active comparator. Among the
20 published trials, 15 (two-thirds) were FDA-positive; the five that
were not positive showed some evidence of outcome reporting bias.
However, the association between trial outcome and publication
status was not statistically significant. The mean effect size derived
from the published literature was only slightly higher than that
derived from the FDAreviews, and the difference between them did
notreachstatisticalsignificance. Ontheotherhand,withintheFDA
dataset, the mean effect size of the published trials was
approximately double that of the unpublished trials.
Publication Bias and Antipsychotics
Previous work on publication bias among antipsychotic trials
has focused on alleged advantages of specific antipsychotics over
one another [43,44]. And within the context of a meta-analysis of
second-generation antipsychotics, small study bias was suggested
by an asymmetric funnel plot [45]. In the present study, FDA data
provided a relatively unbiased control dataset with which to
measure the influence of publication bias on apparent drug
efficacy. Our approach is perhaps best compared to two previous
studies that employed drug regulatory data to examine publication
bias for antidepressants: one by our group, which used FDA data
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data from the Swedish drug regulatory authority [46].
Publication Bias for Antipsychotics versus
Antidepressants
Compared to the findings for antidepressants, these findings for
antipsychotics are less striking. (The overall results for the two drug
classes are compared at the bottom of Figure 3.) We believe this is
fundamentally related to the larger FDA-based effect size for
antipsychotics compared to antidepressants [8], which increases
the probability that, in any given trial, the drug–placebo difference
will reach statistical significance. Indeed, two-thirds of the
antipsychotic trials were positive, compared to one-half of the
antidepressant trials [8]. With a larger proportion of positive trials,
it should not be surprising that a larger proportion of the
antipsychotic trials were published. We do not know whether this
is due to a higher manuscript submission rate by drug companies
and their investigators, a higher acceptance rate by journals, or
both.
As a further consequence of the increased proportion of positive
trials, fewer trials were needed, on a per-drug basis, to attain the
two positive trials required for FDA approval (three here versus
approximately six for antidepressants). This, combined with the
fact that we were working with fewer drugs (eight here versus 12
for antidepressants), led to a smaller total number of trials (24
versus 74) and thereby less statistical power. In the meta-analyses,
the smaller n associated with the unpublished negative and
questionable trials carried little meta-analytic weight relative to the
larger n associated with the positive and published trials. This
diluted the impact of the unpublished trials when the overall effect
size was calculated, leading to a smaller gap between the FDA-
and journal-based overall effect size values (8% here versus 32%
for antidepressants).
Comparing drug classes, the published literature suggests that
the effect size for antipsychotics is only slightly greater than that for
antidepressants, but FDA data reveal that the effect size gap
between these two drug classes is much larger (Figure 3). A similar
discrepancy between published and FDA data can be seen when
one compares the proportion of positive trials for the two drug
classes. Examined either way, publication bias can blur distinctions
between effective and ineffective drugs.
Effect Size in Context
The overall effect size we found, 0.44, was somewhat lower than
those from two previous meta-analyses that also made use of FDA
data from placebo-controlled trials, probably because of method-
ological differences. One of these meta-analyses [45] reported an
overall effect size of 0.51. It covered somewhat different drugs and
comingled (limited) FDA data with published data, while we
deliberately kept these two data sources separate in order to
contrast them. The other meta-analysis [47] reported an effect size
of 0.53. It was based on FDA data exclusively, but it covered only
three of the eight drugs in the present study. That meta-analysis
was published before FDA data became available on the two drugs
found in this study to have the lowest effect sizes, ziprasidone (0.30)
and iloperidone (0.28).
Because the effect size point estimate of 0.44 is less than 0.5,
there is the risk that some parties will declare that antipsychotics
have failed a critical litmus test for clinical significance, as has been
declared for antidepressants [48,49]. Space does not permit a full
discussion as to why this reasoning is problematic [50], but we will
touch briefly on some of the issues. (1) This 0.5 cutoff seems to
derive from Cohen’s [51] suggestion that 0.5 be used as a
landmark for a medium effect, but Cohen never mentioned
clinical significance nor, for that matter, clinical trials. (2) In
proposing these landmarks, Cohen cautioned, ‘‘The values chosen
had no more reliable a basis than my own intuition.’’ Put another
way, they are not evidence-based. (3) It seems simplistic to think
that one cutoff should apply uniformly across all fields of scientific
inquiry, including all classes of drugs. Rather, as has been stated,
‘‘The most challenging and urgent task remains unsolved:
developing the principles that underlie the thresholds of clinical
significance in different clinical contexts’’ [52]. (4) Because of
publication bias, effect sizes derived from the published literature
should be interpreted with some caution. Some effect sizes that
appear to exceed 0.5 might need to be revised downward once
they are recalculated using data that are less vulnerable to
publication bias, such as FDA data. Until such time, considering
the evidence that publication bias is pervasive throughout
medicine [3], we believe that any decisions on thresholds for
clinical significance are premature.
Limitations
Lack of statistical power, due to the small number of trials
analyzed (see above), was a major limitation of this study. Because
of this, some of the statistically nonsignificant results could
represent type II error (false negatives). Further, the statistical test
for trial outcome versus publication status examined whether trials
were published but not how they were published (outcome
reporting bias).
Although the forest plots might seem to suggest significant
between-drug differences, this study was not designed to address
comparative effectiveness. The degree of heterogeneity is unclear:
the 95% confidence intervals around I
2 were wide, as appears to
be the case in the majority of meta-analyses of medical
interventions [29].
While this study addresses the efficacy of antipsychotics, it does
not address their safety, an integral component of the clinician’s
risk–benefit analysis, nor their ‘‘real world’’ effectiveness [53]. In
the trials we studied, efficacy was measured using scales that give
little weight to disabling cognitive and negative symptoms [54].
These data apply only to adult, not pediatric or geriatric, patients.
And they apply only to schizophrenia and schizoaffective disorder,
not to other conditions for which these drugs are used.
This study assumes that the FDA database serves as a gold
standard that is complete and unbiased, but caveats must be
acknowledged. Drug companies must register trials with the FDA
before they can begin them, but this applies only if the drug
company is already pursuing marketing authorization in the US.
Sometimes drug companies conduct clinical trials programs and
obtain marketing approval outside the US and only approach the
FDA at a later point in time. In such cases it is conceivable that the
FDA, having not had the benefit of a priori trial registration, might
not learn about the existence of certain non-US trials. A second
caveat arises from the fact that what the FDA routinely makes
publicly available, the drug approval packages [5,11], contain data
primarily from premarketing trials. Postmarketing trials are
generally omitted, and these may represent the majority of the
trials conducted on a given drug.
Implications
Selective reporting of research results undermines the integrity
of the evidence base, which ultimately deprives clinicians of
accurate data for prescribing decisions. With further studies
investigating publication bias in other drug classes, a more
accurate evidence base can emerge. To that end, increased access
to FDA reviews has been advocated [5,55]. At the present time,
the FDA is not as transparent with its clinical trial data as it could
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several antipsychotic drugs were posted on the FDA web site, but
only for the original indication of schizophrenia and not for
bipolar mania [5]. More than seven years later, the mania reviews
remain inaccessible. On the other hand, it is encouraging that the
FDA has convened a Transparency Task Force [56]. If the agency
fulfills its mission to increase transparency, the public health will
surely benefit.
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Background. People assume that, when they are ill, health-
care professionals will ensure that they get the best available
treatment. But how do clinicians know which treatment is
likely to be most effective? In the past, clinicians used their
own experience to make such decisions. Nowadays, they rely
on evidence-based medicine—the systematic review and
appraisal of trials, studies that investigate the efficacy and
safety of medical interventions in patients. Evidence-based
medicine can guide clinicians, however, only if all the results
from clinical trials are published in an unbiased manner.
Unfortunately, ‘‘publication bias’’ is common. For example,
the results of trials in which a new drug did not perform
better than existing drugs or in which it had unwanted side
effects often remain unpublished. Moreover, published trials
can be subject to outcome reporting bias—the publication
may only include those trial outcomes that support the use
of the new treatment rather than presenting all the available
data.
Why Was This Study Done? Ifonly strongly positiveresults
are published and negative results and side-effects remain
unpublished, a drug will seem safer and more effective than it
is in reality, which could affect clinical decision-making and
patient outcomes. But how big a problem is publication bias?
Here, researchers use US Food and Drug Administration (FDA)
reviews as a benchmark to quantify the extent to which
publication bias may be altering the apparent efficacy of
second-generation antipsychotics (drugs used to treat
schizophrenia and other mental illnesses that are chara-
cterized by a loss of contact with reality). In the US, all new
drugs have to be approved by the FDA before they can be
marketed. During this approval process, the FDA collects and
keeps complete information about premarketing trials, in-
cluding descriptions of their design and prespecified outcome
measures and all the data collected during the trials. Thus, a
comparison of the results included in the FDA reviews for a
group of trials and the results that appear in the literature for
the same trials can provide direct evidence about publication
bias.
What Did the Researchers Do and Find? The researchers
identified 24 FDA-registered premarketing trials that investi-
gated the use of eight second-generation antipsychotics for
the treatment of schizophrenia or schizoaffective disorder.
They searched the published literature for reports of these
trials, and, by comparing the results of these trials according to
the FDA with the results in the published articles, they
examined the relationship between the study outcome (did
the FDA consider it positive or negative?) and publication and
looked for outcome reporting bias. Four of the 24 FDA-
registered trials were unpublished. Three of these unpublished
trials failed to show that the study drug was more effective
than a placebo (a ‘‘dummy’’ pill); the fourth showed that the
study drug was inferior to another drug already in use in the
US. Among the 20 published trials, the five that the FDA
judged not positive showed some evidence of publication
bias. However, the association between trial outcome and
publicationstatusdidnotreachstatisticalsignificance(itmight
have happened by chance), and the mean effect size (a
measure of drug effectiveness) derived from the published
literature was only slightly higher than that derived from the
FDA records. By contrast, within the FDA dataset, the mean
effect size of the published trials was approximately double
that of the unpublished trials.
What Do These Findings Mean? The accuracy of these
findings is limited by the small number of trials analyzed.
Moreover, this study considers only the efficacy and not the
safety of these drugs, it assumes that the FDA database is
complete and unbiased, and its findings are not generalizable
to other conditions that antipsychotics are used to treat.
Nevertheless, these findings show that publication bias in the
reporting of trials of second-generation antipsychotic drugs
enhances the apparent efficacy of these drugs. Although the
magnitude of the publication bias seen here is less than that
seen in a similar study of antidepressant drugs, these findings
show how selective reporting of clinical trial data undermines
the integrityoftheevidencebaseand candeprive clinicians of
accurate data on which to base their prescribing decisions.
Increased access to FDA reviews, suggest the researchers, is
therefore essential to prevent publication bias continuing to
blur distinctions between effective and ineffective drugs.
Additional Information. Please access these web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001189.
N The US Food and Drug Administration provides informa-
tion about drug approval in the US for consumers and
health-care professionals
N Detailed information about the process by which drugs are
approved is on the web site of the FDA Center for Drug
Evaluation and Research; also, FDA Drug Approval
Packages are available for many drugs; the FDA
Transparency Initiative, which was launched in June
2009, is an agency-wide effort to improve the transparency
of the FDA
N FDA-approved product labeling on drugs marketed in the
US can be found at the US National Library of Medicine’s
DailyMed web page
N Wikipedia has a page on publication bias (note: Wikipedia
is a free online encyclopedia that anyone can edit;
available in several languages)
N MedlinePlus provides links to sources of information on
schizophrenia and on psychotic disorders (in English and
Spanish)
N Patient experiences of psychosis, including the effects of
medication, are provided by the charity HealthtalkOnline
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